SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disordersJosé Luís Piñana, David Navarro, Lucía López‐Corral et al.|Journal of Hematology & Oncology|2022Cited by 39
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA RegistryClaudia Sargas, Mar Tormo, Pilar Martínez‐Sánchez et al.|Cancers|2023Cited by 30
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA groupClaudia Sargas, Rosa Ayala, María José Larráyoz et al.|Blood Cancer Journal|2023Cited by 28
Quizartinib for Newly Diagnosed <i>FLT3</i> -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI StudyPau Montesinos, Jorge Labrador, Rebeca Rodríguez‐Veiga et al.|Journal of Clinical Oncology|2025Cited by 13
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical TrialRosa Ayala, Inmaculada Rapado, Esther Onecha et al.|Cancers|2021Cited by 12